Reference Detail

Ref Type

Journal Article

PMID

(32494639)

Authors

Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA

Title

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Science advances	6	17	2020 04	eaaz3221	Sci Adv

URL

Abstract Text

Mutations in isocitrate dehydrogenase (IDH) genes occur in multiple cancer types, lead to global changes in the epigenome, and drive tumorigenesis. Yet, effective strategies targeting solid tumors harboring IDH mutations remain elusive. Here, we demonstrate that IDH-mutant gliomas and cholangiocarcinomas display elevated DNA damage. Using multiple in vitro and preclinical animal models of glioma and cholangiocarcinoma, we developed treatment strategies that use a synthetic lethality approach targeting the reduced DNA damage repair conferred by mutant IDH using poly(adenosine 5'-diphosphate) ribose polymerase inhibitors (PARPis). The therapeutic effects are markedly enhanced by cotreatment with concurrent, localized radiation therapy. PARPi-buttressed multimodality therapies may represent a readily applicable approach that is selective for IDH-mutant tumor cells and has potential to improve outcomes in multiple cancers.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 7 of 7 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
IDH1 mutant	high grade glioma	sensitive	Radiotherapy + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Veliparib (ABT-888) enhanced the sensitivity of a glioma cell line xenograft model harboring an IDH1 mutation to radiation therapy, resulting in increased survival compared to radiation therapy alone, with a median overall survival of 21 days vs 14 days, respectively (PMID: 32494639).	32494639
IDH1 R132H	high grade glioma	sensitive	Radiotherapy + Veliparib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Veliparib (ABT-888) enhanced sensitivity to radiation therapy in immortalized astrocytes expressing IDH1 R132H in culture, resulting in greater decreased colony formation, and in a glioma cell line xenograft model, resulting in both increased tumor regression and survival compared to radiation therapy alone, with a median overall survival of 66 days vs 22 days, respectively (PMID: 32494639).	32494639
IDH1 R132H	high grade glioma	sensitive	Pamiparib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Pamiparib (BGB-290) enhanced the sensitivity of a glioma cell line expressing IDH1 R132H to radiation therapy, resulting in a reduction in tumor volume and increased survival compared to radiation therapy alone in a cell line xenograft model (PMID: 32494639).	32494639
IDH1 R132H	intrahepatic cholangiocarcinoma	sensitive	Olaparib + Radiotherapy	Preclinical - Cell line xenograft	Actionable	In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of an intrahepatic cholangiocarcinoma cell line expressing IDH1 R132H to radiation therapy, resulting in decreased survival in culture and delayed tumor growth and increased survival compared to radiation therapy alone in a cell line xenograft model, with a median overall survival of 60 days vs 47 days, respectively (PMID: 32494639).	32494639
IDH1 mutant	high grade glioma	sensitive	Olaparib + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of a glioma cell line harboring an IDH1 mutation to radiation therapy in culture, resulting in decreased survival compared to radiation therapy alone (PMID: 32494639).	32494639
IDH1 R132C	intrahepatic cholangiocarcinoma	sensitive	Olaparib + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of an intrahepatic cholangiocarcinoma cell line harboring IDH1 R132C to radiation therapy in culture, resulting in decreased survival compared to radiation therapy alone (PMID: 32494639).	32494639
IDH1 R132H	high grade glioma	sensitive	Olaparib + Radiotherapy	Preclinical - Cell culture	Actionable	In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of immortalized astrocytes expressing IDH1 R132H to radiation therapy in culture, resulting in increased cell death and decreased colony formation compared to radiation therapy alone (PMID: 32494639).	32494639

Showing 1 to 7 of 7 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting